NRX Pharmaceuticals
NRXP
20 hedge funds and large institutions have $45.4M invested in NRX Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
2% more capital invested
Capital invested by funds: $44.7M → $45.4M (+$703K)
0% more funds holding
Funds holding: 20 → 20 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.11% less ownership
Funds ownership: 4.96% → 4.86% (-0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$2.51M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.13M |
| 3 |
MSU
Mizuho Securities USA
New York
|
+$1.08M |
| 4 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
+$765K |
| 5 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
+$269K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$3.08M |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$2.57M |
| 3 |
GCL
Glazer Capital LLC
New York
|
-$163K |
| 4 |
CI
Cowen Inc
New York
|
-$159K |
| 5 |
BCM
Bluefin Capital Management
New York
|
-$39K |
NRXP Hedge Fund Activity: Q1 2019 in Review
20 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q1 2019, worth a combined $45.4M — up 1.6% from $44.7M a quarter earlier.
Fund positioning in NRXP was balanced in Q1 2019: 2 funds opened new positions, 2 closed out, 6 added to existing stakes and 4 trimmed.
The largest buyer was Weiss Asset Management, adding an estimated $2.51M. The largest seller was Polar Asset Management Partners, cutting an estimated $3.08M.
- 20 institutional investors held NRX Pharmaceuticals (NRXP) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $45.4M of NRX Pharmaceuticals stock for Q1 2019, up 1.6% quarter-over-quarter.
- 2 funds opened new NRX Pharmaceuticals positions in Q1 2019 and 2 closed out, a net change of 0 holders.
- The largest NRX Pharmaceuticals buyer in Q1 2019 was Weiss Asset Management, an estimated $2.51M added.
- The largest NRX Pharmaceuticals seller in Q1 2019 was Polar Asset Management Partners, an estimated $3.08M sold.
Based on aggregated 13F filings for Q1 2019.